

## Review Article

# Oxidative Stress-Derived Mitochondrial Dysfunction in Chronic Obstructive Pulmonary Disease: A Concise Review

Mariana A. Antunes <sup>1,2</sup>, Miquéias Lopes-Pacheco <sup>1</sup> and Patricia R. M. Rocco <sup>1,2,3</sup>

<sup>1</sup>Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

<sup>2</sup>National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil

<sup>3</sup>Rio de Janeiro Innovation Network in Nanosystems for Health-NanoSAÚDE/FAPERJ, Rio de Janeiro, Rio de Janeiro, Brazil

Correspondence should be addressed to Patricia R. M. Rocco; prmrocco@gmail.com

Received 9 November 2020; Revised 27 January 2021; Accepted 26 February 2021; Published 12 March 2021

Academic Editor: Emiliano Barreto

Copyright © 2021 Mariana A. Antunes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic obstructive pulmonary disease (COPD) is a progressive and disabling disorder marked by airflow limitation and extensive destruction of lung parenchyma. Cigarette smoke is the major risk factor for COPD development and has been associated with increased oxidant burden on multiple cell types in the lungs. Elevated levels of reactive oxygen species (ROS) may significantly affect expression of biological molecules, signaling pathways, and function of antioxidant defenses. Although inflammatory cells, such as neutrophils and macrophages, contribute to the release of large quantities of ROS, mitochondrial dysfunction plays a critical role in ROS production due to oxidative phosphorylation. Although mitochondria are dynamic organelles, excess oxidative stress is able to alter mitochondrial function, morphology, and RNA and protein content. Indeed, mitochondria may change their shape by undergoing fusion (regulated by mitofusin 1, mitofusin 2, and optic atrophy 1 proteins) and fission (regulated by dynamin-related protein 1), which are essential processes to maintain a healthy and functional mitochondrial network. Cigarette smoke can induce mitochondrial hyperfusion, thus reducing mitochondrial quality control and cellular stress resistance. Furthermore, diminished levels of enzymes involved in the mitophagy process, such as Parkin (a ubiquitin ligase E3) and the PTEN-induced putative kinase 1 (PINK1), are commonly observed in COPD and correlate directly with faulty removal of dysfunctional mitochondria and consequent cell senescence in this disorder. In this review, we highlight the main mechanisms for the regulation of mitochondrial quality and how they are affected by oxidative stress during COPD development and progression.

## 1. Introduction

Chronic obstructive pulmonary disease (COPD) is a slowly progressive pulmonary disorder that affects over 300 million people worldwide. The Global Initiative for Chronic Obstructive Lung Disease currently estimates that 3 million people die annually due to COPD, a proportion that is expected to rise over the following 40 years as smoking becomes more prevalent in developing countries and populations grow older in high-income countries. COPD is an avoidable, treatable disease, which is characterized by progressive airflow limitation that may be fully or partly irreversible [1]. Corticosteroids are considered the gold-standard therapy for COPD; they alleviate patients' symptoms and increase the interval between

exacerbations, with a potential delay in the decline of lung function. However, corticosteroids do not prevent disease progression, and a portion of patients do not benefit from these therapies due to smoking-induced steroid resistance [2].

Airflow limitation is frequently associated with an augmented, chronic inflammatory response and tissue remodeling in both airways and lung parenchyma, and occurs due to exposure to noxious particles or gases. Furthermore, comorbid disorders and exacerbations are directly linked to COPD severity [1, 3]. Cigarette smoke is the predominant risk factor for COPD, as it contains a large amount of substances that stimulate the production of reactive oxygen species (ROS), thus inducing an oxidant burden [4, 5]. In nonsmokers, COPD results from a complex interplay between long-term

exposure to noxious particles and gases (e.g., occupational exposures to vapors, gases, dusts, or fumes) and individual genetic susceptibility (e.g.,  $\alpha$ -1 antitrypsin deficiency) [6].

Oxidative stress originates from an imbalance between oxidants derived from ROS and endogenous antioxidant production. In COPD, endogenous and exogenous oxidants are related to disease development [7]. In the chemical process of oxidation, electrons are withdrawn from molecules; leaked electrons then lead to the synthesis of reactive free radicals. Environmental pollutants and inhaled toxic gases, including industrial pollution, car exhaust fumes, occupational exposure to dusts, and cigarette smoking, are major exogenous sources of ROS production [8].

Among the endogenous sources of ROS, mitochondria are one of the main components involved in oxidant production. Mitochondrial ROS may be derived from up to 12 potential sites associated with nutrient oxidation and the electron transport chain (ETC), divided into two subgroups: the reduced nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide (NADH/NAD<sup>+</sup>) isopotential group and the ubiquinol/reduced ubiquinone (UQH<sub>2</sub>/UQ) isopotential group. These different sites make variable contributions to the overall release of O<sub>2</sub><sup>-</sup>/H<sub>2</sub>O<sub>2</sub> depending on cell type and tissue, which seems to be related to substrate availability and mitochondrial bioenergetics (Table 1) [9, 10]. In the ETC, electrons are transported through four respiratory chain complexes: complex I (NADH-coenzyme Q reductase), complex II (succinate dehydrogenase), complex III (coenzyme Q-cytochrome c reductase), and complex IV (cytochrome c oxidase), finally reacting with molecular oxygen, resulting in superoxide (O<sub>2</sub><sup>-</sup>) production. Energy produced while electrons are carried through the ETC is used to pump protons into the intermembrane space, creating an electrochemical proton gradient ( $\Delta\psi_m$ ) that is used by ATP synthase to generate ATP. Some electrons leak into the matrix and react with molecular oxygen to generate O<sub>2</sub><sup>-</sup>, at several different sites, such as the oxoacid dehydrogenase complexes (which feed electrons to NAD<sup>+</sup>), ETC complexes I and III, and dehydrogenases, including ETC complex II. Thereafter, O<sub>2</sub><sup>-</sup> is further converted into hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by superoxide dismutase (SOD). In the mitochondria, H<sub>2</sub>O<sub>2</sub> is buffered by glutathione (GSH), thioredoxin/peroxiredoxins, and catalase systems [10]. Hence, high concentrations of O<sub>2</sub><sup>-</sup> play a key role in excess ROS production.

## 2. Neutrophil-Derived ROS in COPD

The cell damage and death observed in COPD airways have been attributed to oxidative stress triggered after smoking or air pollution exposure [11]. In a proportion of smokers who develop COPD, smoking cessation does not halt the disease progression, suggesting that an endogenous source promotes self-perpetuation of inflammation and tissue injury in these susceptible individuals [12–14]. The continuous release of inflammatory mediators (e.g., leukotriene B<sub>4</sub> and interleukin-8) induces the recruitment and activation of additional inflammatory cells (especially neutrophils) into the lungs, which release further proteases, free radicals, and

cytokines that promote destruction of the lung parenchyma, loss of lung elasticity [15], and hypersecretion of mucus [16].

Neutrophils from COPD patients exhibit several abnormal features, including secretion of elevated levels of ROS [17–19], high speed and low migration accuracy [20], and high levels of activation and degranulation of surface markers (CD63 expression) [21]. Indeed, degranulation products (e.g., inflammatory cytokines, ROS, and neutrophil elastase) increase inflammatory signaling and protease load in the lung tissue of individuals with COPD. Cigarette smoke increases IL-8 production in lung epithelial cells, acting as a chemoattractant for neutrophils, which release neutrophil elastase and promote degradation of the extracellular matrix components of lung tissue [22]. Neutrophil elastase not only digests extracellular matrix protein components [23] but also contributes to the loss of bronchial epithelial cells [22] and mucus hypersecretion by goblet cells [24]. Although  $\alpha$ 1AT is a hepatic antielastase that is physiologically able to inhibit neutrophil elastase [25], excess ROS can promote oxidation of the methionine residue at position 358 of the  $\alpha$ 1AT polypeptide chain [26, 27], resulting in its inactivation and leading to lung inflammation and tissue destruction. Furthermore, neutrophil myeloperoxidase catalyzes the oxidation reaction of chloride ions (Cl<sup>-</sup>) by hydrogen peroxide to generate the anionic ROS hypochlorite or hypochlorous acid (HClO); in turn, HClO reacts with low-molecular-weight amines (e.g., nicotine) to produce chloramines, which lead to cellular protein damage [28].

## 3. Oxidative Mitochondrial Dysfunction in COPD

A reduction in mitochondrial function—characterized by lower mitochondrial membrane potential, changes in ETC complex activities, diminished ATP synthesis, inefficient Ca<sup>2+</sup> buffering, increased ROS production, altered mitochondrial dynamics, or release of proapoptotic factors—is observed during aging and in the course of many chronic diseases, including COPD. At baseline, as a result of mitochondrial oxidative phosphorylation, cells produce ROS from a minimal level of residual, unreduced molecular oxygen [29]. However, in the presence of harmful stimuli, the amount of mitochondrial ROS (mtROS) increases substantially. Each puff of cigarette smoke carries  $\sim 10^{17}$  oxidant molecules [5], including ROS such as superoxide, hydrogen peroxide, and hydroxyl anion, which may cause extensive damage to DNA, proteins, lipids, and organelles such as mitochondria. There is also degradation of mitochondrial DNA (mtDNA), which is much more likely to suffer oxidative damage than nuclear DNA and lacks elaborate repair machinery [30, 31]. The lipophilic fraction of cigarette smoke (including polycyclic aromatic hydrocarbons, aldehydes, amines, heavy metals, and phenolic compounds) is responsible for a reduction in mitochondrial membrane potential and ATP production, as well as concomitant generation of mtROS [32]. Adverse effects of cigarette smoke on mitochondrial respiratory function have already been described in several cell types, including cardiomyocytes (decrease in maximum respiration) [33], lymphocytes (reduction in

TABLE 1: Mitochondrial sources of ROS production.

Isopotential group	Enzyme	Site of production	Tissue/organ
NADH/NAD <sup>+</sup>	$\alpha$ -Ketoglutarate dehydrogenase (KGDH)	FAD	Liver, skeletal muscle
	Pyruvate dehydrogenase (PDH)	FAD	Liver, skeletal muscle
	Branched-chain keto acid dehydrogenase	FAD	Skeletal muscle
	2-Oxoadipate dehydrogenase	FAD	Skeletal muscle
	Complex I	FMN	Cardiac muscle
	Complex I	UQ binding site	Skeletal muscle
	Complex II	FAD	Skeletal muscle, cardiac muscle, liver
UQH <sub>2</sub> /UQ	Complex III	UQ binding site	Skeletal muscle, cardiac muscle, liver
	Electron transfer flavoprotein: ubiquinone oxidoreductase	FAD	Undetermined
	<i>sn</i> -Glycerol-3-phosphate dehydrogenase (3GPDH)	FAD	Skeletal muscle, cardiac muscle, liver
	Proline dehydrogenase	FAD	Undetermined
	Dihydroorotate dehydrogenase	FAD	Undetermined

NADH/NAD<sup>+</sup>: reduced nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide isopotential group; UQH<sub>2</sub>/UQ: ubiquinol/reduced ubiquinone isopotential group; FAD: flavin adenine dinucleotide.

complex IV activity) [34], and monocytes (impairment of mitochondrial membrane potential and apoptosis) [35]. Similarly, cigarette smoke causes direct damage to airway epithelial cells, resulting in airway inflammation involving several immune cells (e.g., neutrophils, macrophages, and lymphocytes) [1, 36]. Stress induced-mtROS also stimulate the release of mitochondrial damage-associated molecular patterns (mt-DAMPs) into the cytosol or extracellular space [37, 38] and activate the innate immune responses in lung tissue via pattern recognition receptors (PRRs) on the plasma membrane of alveolar epithelial cells and macrophages, resulting in further production of inflammatory cytokines via a caspase 1-dependent mechanism and formation of the nucleotide-binding oligomerization domain like receptor (NLR) P3 inflammasome, which induces the secretion of multiple interleukins related to type-1 airway inflammation [39, 40].

Long-term exposure to cigarette smoke leads to dysfunctional, elongated mitochondria, with fragmentation and disruption of mitochondrial cristae in COPD bronchial epithelial cells, resulting in extensive apoptosis and cellular senescence [41]. Alteration of mitochondrial biogenesis and mitophagy in the skeletal muscle cells of COPD patients may also contribute to loss of muscle strength [42], playing a role in the reduction in exercise endurance. COPD patients may exhibit reduced mitochondrial biogenesis, dysfunctional oxidative phosphorylation, and augmented mtROS production and diminished mitochondrial uncoupling protein-3 in skeletal muscle and airway smooth muscle (ASM) cells [43, 44]. In addition to an increased amount of mtROS, ASM cells from COPD patients also exhibit reduced mitochondrial membrane potential, ATP content, and basal and maximum respiration levels, which are associated with increased levels of biomarkers of inflammation (e.g., interleukin-6 and -8) and cell proliferation (granulocyte-macrophage colony-stimulating factor) [42].

Short-term exposure to cigarette smoke has been demonstrated to upregulate the expression of complexes II, III, IV, and V and the activity of complexes II, IV, and V in pulmonary cell mitochondria, which are slightly reduced compared

to control values after removing smoking stimuli. However, cigarette smoking irreversibly decreases the expression and activity of complex I after an 8-week exposure [45]. This reduction suggests a complex II-driven oxidative phosphorylation induced by cigarette smoke. Indeed, this metabolic profile is accompanied by a redox response, which encompasses changes in the cellular and mitochondrial levels of pyridine nucleotides (oxidized and reduced nicotinamide adenine dinucleotides in their unphosphorylated—NAD<sup>+</sup> or NADH—and phosphorylated—NADP<sup>+</sup> or NADPH—states) and glutathione. Cigarette smoke exposure also induces a highly reduced environment in the mitochondrion, which is related to increased expression of the mitochondrial NADPH-generating enzymes isocitrate dehydrogenase-2 (IDH2) and nicotinamide nucleotide transhydrogenase (NNT) [45]. Accordingly, Cormier et al. [46] demonstrated that nicotine—the primary addictive component of tobacco smoke—binds to ETC complex I and inhibits its NADH-ubiquinone reductase activity in brain mitochondria. Nicotine binding results in inhibition of electron flow from NADH to complex I [46], which is associated with a detectable decrease in oxygen consumption by mitochondria. Several studies have demonstrated that nicotine may affect other ETC complexes (II-IV) as well [47–49], but the potential inhibitory effects of nicotine on these other complexes have yet to be completely elucidated. Primary human lung epithelial cells (SAEC and NHBE) are also sensitive to cigarette smoke extract; 15-day treatment *in vitro* promoted a significant reduction in levels of ETC complexes I, II, III, and IV, while protein expression of complex V remained unaffected [50].

Mitochondria also seem to be an intracellular target for cadmium, a heavy metal that is found in tobacco smoke. In renal epithelium, cadmium directly compromised mitochondrial function by increasing mitochondrial permeability and swelling, thus inhibiting respiration and increasing ROS production [51]. Although the pathological mechanisms of cadmium toxicity in mitochondria have not been completely elucidated, it has been reported to accumulate intracellularly

and affect both mitochondrial ETC and membrane permeability [52]. In addition, cadmium is a powerful uncoupling agent that inhibits succinate- and malate/pyruvate-stimulated respiration. Cadmium interacts with complex I at the ubiquinone and NADH sites, resulting in complex I inhibition in rat hepatic mitochondria. Finally, cadmium exposure inhibits complex IV (cytochrome c oxidase) by inhibiting ETC downstream ubiquinone [53].

**3.1. Altered Mitochondrial Dynamics.** Mitochondrial morphology is maintained within a fine balance between two opposite processes: fusion and fission [54, 55]. Proteins involved in the regulation of mitochondrial morphology and maintenance of the fission-fusion balance are necessary for overall cellular health. Mitochondrial fission is necessary to preserve an ideal number of mitochondria during cellular growth and division processes, while fusion enables the unification of mitochondrial compartments. Mitochondrial fusion has been reported as a strategy to protect cells against mitochondrial DNA (mtDNA) mutations by allowing functional complementation of mtDNA genes [56]. Elongated mitochondria are preserved from mitophagy, exhibit more cristae and augmented ATP synthase activity, and are able to ensure ATP production [57]. Nevertheless, prolonged permanence of mitochondria in the elongated state may contribute to higher intracellular ROS and lower mitochondrial respiration, leading to cellular senescence—a major factor in the pathogenesis cascade of COPD [58].

There are three large guanosine triphosphatases (GTPases) responsible for the mitochondrial fusion process: mitofusion (Mfn) 1 and Mfn2 (both in the mitochondrial outer membrane), and optic atrophy protein 1 (Opa1), in the mitochondrial inner membrane. Long-term exposure to cigarette smoke has been shown to induce morphologic changes in the mitochondrial structure of human bronchial epithelial cells, including fragmentation, branching, and altered number of cristae, accompanied by a significant increase in fission and fusion markers, oxidative phosphorylation proteins, and oxidative stress markers (e.g., manganese superoxide dismutase) [41]. In baseline conditions, Mfn2 helps to maintain mitochondrial networks with elongated branching, while fission proteins have a less prominent role. Following cigarette smoke exposure, Mfn2 expression and function are diminished in human airway smooth muscle cells, while an increase in expression of mitochondrial fission protein (dynammin-related protein 1, Drp1) is observed [59]. On the other hand, cigarette smoke has been shown to markedly increase expression of Mfn1, Mfn2, and Opa1 in airway epithelial cells [41]. Elongated mitochondria have also been observed in alveolar epithelial cells and lung fibroblasts [60, 61], accompanied by reduced ATP levels [60] and cellular senescence.

Exposure to cigarette smoke facilitates mitochondrial fission in human smooth muscle cells, which may contribute to cellular apoptosis and mitophagy in COPD [59]. The most relevant mediator in this process is the fission protein dynammin-related protein 1 (Drp1). Drp1 translocates from the cytosol to the outer mitochondrial matrix, where it interacts with the human fission protein-1, mitochondrial fission

factor, and mitochondrial dynamics proteins of 49 kDa and 51 kDa, and oligomerizes to form a spiral that leads to constriction and breakage of mitochondrial membranes. Mitochondrial fission ensures equal division of mitochondrial numbers during cell division and mediates the selective removal of damaged mitochondria by mitophagy. Sundar et al. [50] showed that, *in vitro*, cigarette smoke extract-treated primary human lung epithelial cells developed an imbalance of proteins involved in mitochondrial fission (augmented Drp1) and fusion (diminished Mfn2). Additionally, Aravamudan et al. [59] found that cigarette smoking-induced mitochondrial ROS accelerates the course of phosphorylation of Drp1 in human airway smooth muscle cells, leading to mitochondrial fragmentation. Drp1 inhibition prevented the effects of cigarette smoke on mitochondrial morphology changes, which are mediated by multiple signaling and transcriptional pathways that are relevant to COPD pathogenesis. These include activation of extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), protein kinase C (PKC), and proteasome pathways, as well as transcriptional regulation via factors such as NF- $\kappa$ B and nuclear erythroid 2-related factor 2 [59].

**3.2. Impaired Mitophagy.** Mitochondrial autophagy, known as mitophagy, plays a pivotal role in the removal of damaged mitochondria. However, several reports have demonstrated that cigarette smoke may lead to impaired mitophagy, resulting in accumulation of damaged mitochondria in the cytoplasm, where they are able to form a perinuclear cluster and induce damage to nuclear DNA (due to excess mtROS) and cellular senescence [60, 62]. Mitophagy is an important process to maintain a healthy intracellular environment by removing damaged or dysfunctional mitochondria [63–65]. The maintenance of the  $\Delta\psi_m$  is a *sine qua non* condition for mitochondrial ATP synthesis. Membrane depolarization below a certain  $\Delta\psi_m$  may signal dysfunctional mitochondria and is a prerequisite for mitophagy [66–68] (Figure 1). Although essential, mitochondrial depolarization alone does not initiate mitophagy, which only begins when mitochondria are depolarized and fail to regain their membrane potential to protect themselves from detrimental effects. This process engages the translocation of cytosolic proteins that tag mitochondria for mitophagy. These include an E3 ubiquitin ligase (Parkin) and the PTEN-induced putative kinase 1 (PINK1), an upstream regulator of Parkin [69, 70]. In the mitochondria, Parkin mediates degradation of Mfn2, which prevents mitochondrial fusion. During this process, damaged mitochondria are encompassed in microtubule-associated protein 1 light-chain 3 (LC3) mediated autophagosomes [71], which fuse with lysosomes to be sequentially eliminated from the cell [63–65, 71, 72].

In isolated mitochondria from human fetal lung fibroblasts (HLF), carbonyl cyanide *m*-chlorophenyl hydrazine (CCCP, a Parkin mitochondrial translocation agent) was used to induce mitochondrial depolarization and to test whether cigarette smoke could impair Parkin mitochondrial translocation (Figure 2). Ahmad et al. [60] reported that cigarette smoke extract not only leads to permanent




FIGURE 1: Mitochondrial dynamics in eukaryotic cells. Diverse processes contribute to generation and degradation of mitochondria within cells. During fission, recognition of activated dynamin-related protein 1 (DRP1) by surface receptors (fission protein 1, mitochondrial fission factor, mitochondrial dynamic protein 49, and mitochondrial dynamic protein 51) leads to fragmentation of the outer mitochondrial membrane (OMM) and formation of a new mitochondrion. Mitochondria may acquire an elongated design by fusion, where mitochondrial membranes tether through fusion proteins in the inner mitochondrial membrane (IMM), such as optic atrophy 1 (OPA1), and OMM, such as mitofusin 1 (MFN1) and MFN2.

mitochondrial dysfunction, inducing defective mitophagy by altering cytosolic Parkin levels and translocation in HLF, but also induces perinuclear mitochondrial accumulation, resulting in DNA damage and cellular senescence. Another cytosolic protein that can interact with Parkin, resulting in its inhibition, is p53. In one study, exposure to cigarette smoke for 15 days induced an increase in cytosolic levels of p53, resulting in its increased association with Parkin, reduced mitochondrial translocation of Parkin and, ultimately, impaired mitophagy [60].

Both PINK1 and Parkin have been associated with the pathogenesis cascade of COPD with respect to the regulation of mitophagy. However, the existing data are still conflicting regarding the status of mitophagy and its role in disease progression. Previous studies reported elevated mitochondrial accumulation of PINK1 and reduction of Parkin expression in COPD lungs, but not in non-COPD smokers, suggesting that an increase in PINK1/Parkin ratio is not only dependent on smoking status but correlates with COPD pathogenesis (Figure 3) [41, 60, 62]. Airway epithelial cells from Parkin knockout mice exposed to cigarette smoke demonstrated accumulation of damaged mitochondria and increased mtROS accompanied by accelerated cellular senescence [73]. However, additional studies have found that mitophagy

activation is not sufficient to decelerate cellular senescence in COPD pathogenesis [60, 62]. *In vitro* overexpression of Parkin, but not of PINK1, attenuated mtROS production and cellular senescence, suggesting that Parkin levels can be the rate-limiting factor in PINK1/Parkin-mediated mitophagy during cigarette smoke exposure [73]. Accordingly, Ito et al. demonstrated that cigarette smoke induces mitochondrial damage, increases mtROS production, and initiates senescence of primary human bronchial epithelial cells (HBECs), which may be reversed by inducing overexpression of Parkin in HBECs [62]. Conversely, Ahmad et al. suggested that Parkin overexpression can restore mitochondrial mass accumulation but does not have a significant impact on cellular senescence when cigarette smoke (15-day exposure) has already established cellular senescence [60].

Besides PINK1/Parkin, which are required for mitochondrial degradation via mitophagy, there are also proteins responsible for mitochondrial biogenesis and maintenance of cellular energetics, such as peroxisome proliferator-activated receptor  $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ), which has been implicated in mitochondrial dysfunction associated with chronic lung diseases. PGC-1 $\alpha$  is an integrator of multiple signaling pathways and plays a central role in the regulation of mitochondrial biogenesis and oxidative stress by




FIGURE 2: Mitophagy regulation. In healthy mitochondria, the kinase PINK1 is constitutively repressed by import into the inner mitochondrial membrane (IMM) and degradation by the rhomboid protease PARL. In uncoupled mitochondria, import of PINK1 into the IMM is avoided, so PINK1 is bypassed from PARL and accumulates in the outer mitochondrial membrane (OMM), acting as a signal to mark dysfunctional mitochondria for Parkin, which then conjugates ubiquitin (Ub) to several proteins on the OMM and mediates proteasomal degradation of mitofusins 1 and 2. Finally, Parkin induces engulfment of the damaged mitochondria by autophagy compartments. Several proteins, including autophagy-related genes (ATGs), beclin-1, microtubule-associated protein 1 light-chain 3 (LC3), and p62, facilitate the formation of autophagosomes.




FIGURE 3: Impaired mitophagy in COPD. In regular conditions, cigarette smoke- (CS-) induced mitochondrial damage stabilizes PINK1 on the outer mitochondrial membrane (OMM), which signals for Parkin recruitment to the mitochondrion from an abundant cytosolic pool, leading to sufficient mitophagy, preventing the accumulation of dysfunctional mitochondria, and slowing cellular senescence. In COPD, decreased levels of cytosolic Parkin seem to be related to insufficient mitophagy, which increases the number of damaged mitochondria with stabilized PINK1, leading to further PRKN reduction by PINK1-mediated proteasomal degradation. In COPD, increased levels of p53, a cytosolic protein capable of inhibiting Parkin, may contribute to the reduced availability of Parkin molecules for proteasomal degradation of PINK1.

mitochondrial transcription factor A (TFAM), which ensures mitochondrial DNA replication during mitochondrial biogenesis. Konokhova et al. [74] demonstrated that transcript levels of regulators of mitochondrial biogenesis and oxidative metabolism are upregulated in COPD; however, single-fiber analyses of oxidative-deficient fibers (cytochrome c oxidase-deficient and succinate dehydrogenase-positive fibers) and normal fibers revealed an impairment in mitochondrial biogenesis in COPD. While healthy individuals exhibit an increase in mtDNA and TFAM protein in oxidative-deficient muscle fibers compared to regular muscle fibers, which suggests a compensatory attempt to increase energy levels in oxidative-deficient cells, COPD patients present similar levels in both oxidative-deficient and regular muscle fibers. Such findings indicate that, although there is an increase in signaling factors for mitochondrial biogenesis in the muscle of patients with COPD, impairment in the translation of such signals precludes the recovery of normal oxidative capacity [74].

#### 4. Antioxidant Defenses in COPD

A series of antioxidant defenses, such as reduced GSH, has been developed by the lungs as the respiratory tract is permanently exposed to external and endogenous oxidative stress. A significant portion of the total GSH produced within the mitochondria is intended to balance endogenous production of ROS as a metabolism byproduct [75]. The enzyme glutamate-cysteine ligase is responsible for regulating the synthesis of GSH [76]. Nevertheless, bronchial epithelial cells and alveolar macrophages of smokers and patients with COPD have demonstrated low levels of GSH [77] and other GSH-dependent antioxidant enzymes (e.g., class-pi glutathione S-transferase, glutathione S-transferase mu 1, and glutathione peroxidase) [78]. The oxidative stress state of COPD induces the occurrence of critical events, such as epithelial permeability, lipid peroxidation, and cellular antioxidant GSH depletion in the alveolar epithelium, leading to apoptosis and inflammation characteristics in the pathological cascade of this disorder. As a protective mechanism against environmental oxidants, the lung epithelial lining fluid contains several antioxidants, including ascorbic acid (vitamin C),  $\alpha$ -tocopherol (vitamin E), and uric acid. Levels of these antioxidants in the lungs appear to correlate inversely with pulmonary dysfunction in COPD (Figure 4). In addition, long-term antioxidant supplementation has been shown to minimize the risk of chronic lung disease development by 10%, as well as to reduce pulmonary carbonyl stress [79, 80]. Lung tissue from COPD patients often exhibits elevated expression of transforming growth factor- $\beta$  (TGF- $\beta$ ), which can inhibit expression of several antioxidant enzymes in airway smooth muscle cells, including catalase and superoxide dismutase 2 (SOD2) [81]. These enzymes are regulated by the transcription factor FOXO3 and play a key role in maintaining a balance in mtROS production. Deficient FOXO3 activity has been reported in association with cigarette smoke-induced inflammation and airspace enlargement in COPD [82]. Furthermore, recent evidence demonstrated that serum antioxidant levels from smokers without COPD are




FIGURE 4: Role of oxidative stress in COPD pathogenesis. Cigarette smoke-induced oxidant burden activates intracellular signaling pathways that result in oxidant-antioxidant imbalance, leading to harmful lung cellular damage. The reduction of pulmonary antioxidant defenses induces changes in mitochondrial dynamics (e.g., elongated mitochondria), impaired clearance of damaged mitochondria (mitophagy), accumulation of dysfunctional mitochondria in the perinuclear region of lung cells, DNA damage, and subsequent cell senescence during COPD pathogenesis.

significantly increased compared to those of smokers with COPD, suggesting that low antioxidant defenses may be related to COPD onset and progression [73]. Nevertheless, further studies are needed to clarify these differences, as no correlation was found between spirometric data and antioxidant levels in healthy nonsmokers, smokers, and COPD patients [83–86].

#### 5. Conclusion

In this concise review, we have provided an overview of some key endogenous sources of oxidative burden and their role in COPD pathogenesis. The oxidative/antioxidative balance is finely maintained by a functional antioxidant system (e.g., GSH, ascorbic acid), aimed at neutralizing ROS production by inflammatory cells (particularly neutrophils) and mitochondria. Prolonged exposure to cigarette smoke induces massive infiltration of neutrophils and an imbalance in mitochondrial function, leading to excessive production of ROS, altered mitophagy, and perinuclear accumulation of defective

mitochondria, which result in DNA damage and cellular senescence in COPD. Conversely, antioxidant levels are drastically reduced in COPD, predisposing to tissue oxidative damage. Although oxidative stress has been correlated with pulmonary and systemic features of COPD, the evidence is still controversial and insufficient to demonstrate whether boosting antioxidant mediators might indeed reverse cellular senescence. Considering the impact of oxidative load on the lives of patients with COPD, antioxidant-target therapies should be further studied with a view to identifying therapeutic strategies with potential impact on quality of life and life expectancy.

### Data Availability

No data were used to support this study.

### Conflicts of Interest

The authors declare no potential conflicts of interests.

### Authors' Contributions

All authors wrote the manuscript and approved the final version.

### Acknowledgments

The authors thank Mrs. Moira Elizabeth Schottler (Rio de Janeiro) for her assistance in editing the manuscript. This study was supported by the Brazilian Council for Scientific and Technological Development (CNPq) (Grant 421067/2016-0, in 2016, and Grant 443824/2018-5), the Rio de Janeiro State Research Foundation (FAPERJ) (Grant E-26/210.910/2016 and Grant E-26/202.766/2018), the National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA) (Grant 465656/2014-5, in 2017), and Programa Redes de Pesquisa em Nanotecnologia no Estado do Rio de Janeiro, FAPERJ (Grant E-26/010.000983/2019, in 2019).

### References

- [1] M. Decramer, W. Janssens, and M. Miravittles, "Chronic obstructive pulmonary disease," *Lancet*, vol. 379, no. 9823, pp. 1341–1351, 2012.
- [2] G. Invernizzi, A. Ruprecht, C. De Marco, R. Mazza, G. Nicolini, and R. Boffi, "Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance," *Respiratory Research*, vol. 10, no. 1, p. 48, 2009.
- [3] S. Mirza, R. D. Clay, M. A. Koslow, and P. D. Scanlon, "COPD guidelines: a review of the 2018 GOLD report," *Mayo Clinic Proceedings*, vol. 93, no. 10, pp. 1488–1502, 2018.
- [4] I. Bernardo, S. Bozinovski, and R. Vlahos, "Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities," *Pharmacology & Therapeutics*, vol. 155, pp. 60–79, 2015.
- [5] H. Yao and I. Rahman, "Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease," *Toxicology and Applied Pharmacology*, vol. 254, no. 2, pp. 72–85, 2011.
- [6] M. Needham and R. A. Stockley, "Exacerbations in 1-antitrypsin deficiency," *The European Respiratory Journal*, vol. 25, no. 6, pp. 992–1000, 2005.
- [7] F. Marotta, Y. Naito, F. Padriani et al., "Redox balance signalling in occupational stress: modification by nutraceutical intervention," *Journal of Biological Regulators and Homeostatic Agents*, vol. 25, no. 2, pp. 221–229, 2011.
- [8] R. Kodgule and S. Salvi, "Exposure to biomass smoke as a cause for airway disease in women and children," *Current Opinion in Allergy and Clinical Immunology*, vol. 12, no. 1, pp. 82–90, 2012.
- [9] M. D. Brand, "Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling," *Free Radical Biology & Medicine*, vol. 100, pp. 14–31, 2016.
- [10] R. J. Mailloux, "Mitochondrial antioxidants and the maintenance of cellular hydrogen peroxide levels," *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 7857251, 10 pages, 2018.
- [11] B. H. Cohen, W. C. Ball JR., S. Brashears et al., "Risk factors in chronic obstructive pulmonary disease (COPD)," *American Journal of Epidemiology*, vol. 105, no. 3, pp. 223–232, 1977.
- [12] N. Louhelainen, P. Ryttila, T. Haahtela, V. L. Kinnula, and R. Djukanovic, "Persistence of oxidant and protease burden in the airways after smoking cessation," *BMC Pulmonary Medicine*, vol. 9, no. 1, p. 25, 2009.
- [13] S. R. Rutgers, D. S. Postma, N. H. ten Hacken et al., "Ongoing airway inflammation in patients with COPD who do not currently smoke," *Thorax*, vol. 55, no. 1, pp. 12–18, 2000.
- [14] L. Taraseviciene-Stewart, I. S. Douglas, P. S. Nana-Sinkam et al., "Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?," *Proceedings of the American Thoracic Society*, vol. 3, no. 8, pp. 687–690, 2006.
- [15] R. E. Russell, A. Thorley, S. V. Culpitt et al., "Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 283, no. 4, pp. L867–L873, 2002.
- [16] J. A. Voynow, L. R. Young, Y. Wang, T. Horger, M. C. Rose, and B. M. Fischer, "Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells," *The American Journal of Physiology*, vol. 276, no. 5, pp. L835–L843, 1999.
- [17] A. Noguera, S. Batle, C. Miralles et al., "Enhanced neutrophil response in chronic obstructive pulmonary disease," *Thorax*, vol. 56, no. 6, pp. 432–437, 2001.
- [18] I. Rahman, D. Morrison, K. Donaldson, and W. MacNee, "Systemic oxidative stress in asthma, COPD, and smokers," *American Journal of Respiratory and Critical Care Medicine*, vol. 154, no. 4, pp. 1055–1060, 1996.
- [19] T. E. Renkema, D. S. Postma, J. A. Noordhoek, H. J. Sluiter, and H. F. Kauffman, "Influence of in vivo prednisolone on increased in vitro O<sub>2</sub>- generation by neutrophils in emphysema," *The European Respiratory Journal*, vol. 6, no. 1, pp. 90–95, 1993.
- [20] E. Sapey, J. A. Stockley, H. Greenwood et al., "Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease," *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 9, pp. 1176–1186, 2011.

- [21] E. Sapey, H. Greenwood, G. Walton et al., "Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence," *Blood*, vol. 123, no. 2, pp. 239–248, 2014.
- [22] K. H. Lee, M. K. Jang, J. H. Seo, S. H. Ryu, J. A. Kim, and Y. H. Chung, "ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications," *Experimental & Molecular Medicine*, vol. 50, no. 7, pp. 1–12, 2018.
- [23] B. Korkmaz, T. Moreau, and F. Gauthier, "Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions," *Biochimie*, vol. 90, no. 2, pp. 227–242, 2008.
- [24] K. Takeyama, C. Agusti, I. Ueki, J. Lausier, L. O. Cardell, and J. A. Nadel, "Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules," *The American Journal of Physiology*, vol. 275, no. 2, pp. L294–L302, 1998.
- [25] J. E. Gadek, G. A. Fells, R. L. Zimmerman, S. I. Rennard, and R. G. Crystal, "Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema," *The Journal of Clinical Investigation*, vol. 68, no. 4, pp. 889–898, 1981.
- [26] H. Carp, F. Miller, J. R. Hoidal, and A. Janoff, "Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 79, no. 6, pp. 2041–2045, 1982.
- [27] N. R. Matheson, P. S. Wong, and J. Travis, "Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase," *Biochemical and Biophysical Research Communications*, vol. 88, no. 2, pp. 402–409, 1979.
- [28] S. A. Salama and R. M. Snapka, "Amino acid chloramine damage to proliferating cell nuclear antigen in mammalian cells," *In Vivo*, vol. 26, no. 4, pp. 501–517, 2012.
- [29] Y. Liu, G. Fiskum, and D. Schubert, "Generation of reactive oxygen species by the mitochondrial electron transport chain," *Journal of Neurochemistry*, vol. 80, no. 5, pp. 780–787, 2002.
- [30] A. T. Akhmedov and J. Marin-Garcia, "Mitochondrial DNA maintenance: an appraisal," *Molecular and Cellular Biochemistry*, vol. 409, no. 1–2, pp. 283–305, 2015.
- [31] S. Anderson, A. T. Bankier, B. G. Barrell et al., "Sequence and organization of the human mitochondrial genome," *Nature*, vol. 290, no. 5806, pp. 457–465, 1981.
- [32] M. van der Toorn, D. Rezayat, H. F. Kauffman et al., "Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 297, no. 1, pp. L109–L114, 2009.
- [33] A. Gvozdjakova, J. Kucharska, and J. Gvozdjak, "Effect of smoking on the oxidative processes of cardiomyocytes," *Cardiology*, vol. 81, no. 2–3, pp. 81–84, 1992.
- [34] O. Miro, J. R. Alonso, D. Jarreta, J. Casademont, A. Urbano-Marquez, and F. Cardellach, "Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes," *Carcinogenesis*, vol. 20, no. 7, pp. 1331–1336, 1999.
- [35] N. Banzet, D. Francois, and B. S. Polla, "Tobacco smoke induces mitochondrial depolarization along with cell death: effects of antioxidants," *Redox Report*, vol. 4, no. 5, pp. 229–236, 2013.
- [36] G. G. Brusselle, G. F. Joos, and K. R. Bracke, "New insights into the immunology of chronic obstructive pulmonary disease," *Lancet*, vol. 378, no. 9795, pp. 1015–1026, 2011.
- [37] S. Grazioli and J. Pugin, "Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases," *Frontiers in Immunology*, vol. 9, p. 832, 2018.
- [38] C. A. Lerner, I. K. Sundar, and I. Rahman, "Mitochondrial redox system, dynamics, and dysfunction in lung inflammation and COPD," *The International Journal of Biochemistry & Cell Biology*, vol. 81, pp. 294–306, 2016.
- [39] C. Brightling and N. Greening, "Airway inflammation in COPD: progress to precision medicine," *European Respiratory Journal*, vol. 54, no. 2, p. 1900651, 2019.
- [40] T. Scambler, J. Holbrook, S. Savic, M. F. McDermott, and D. Peckham, "Autoinflammatory disease in the lung," *Immunology*, vol. 154, no. 4, pp. 563–573, 2018.
- [41] R. F. Hoffmann, S. Zarrintan, S. M. Brandenburg et al., "Prolonged cigarette smoke exposure alters mitochondrial structure and function in airway epithelial cells," *Respiratory Research*, vol. 14, no. 1, p. 97, 2013.
- [42] C. H. Wiegman, C. Michaeloudes, G. Haji et al., "Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease," *The Journal of Allergy and Clinical Immunology*, vol. 136, no. 3, pp. 769–780, 2015.
- [43] H. R. Gosker, P. Schrauwen, R. Broekhuizen et al., "Exercise training restores uncoupling protein-3 content in limb muscles of patients with chronic obstructive pulmonary disease," *American Journal of Physiology. Endocrinology and Metabolism*, vol. 290, no. 5, pp. E976–E981, 2006.
- [44] H. R. Gosker, P. Schrauwen, M. K. Hesselink et al., "Uncoupling protein-3 content is decreased in peripheral skeletal muscle of patients with COPD," *The European Respiratory Journal*, vol. 22, no. 1, pp. 88–93, 2003.
- [45] A. R. Agarwal, L. Zhao, H. Sancheti, I. K. Sundar, I. Rahman, and E. Cadenas, "Short-term cigarette smoke exposure induces reversible changes in energy metabolism and cellular redox status independent of inflammatory responses in mouse lungs," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 303, no. 10, pp. L889–L898, 2012.
- [46] A. Cormier, C. Morin, R. Zini, J. P. Tillement, and G. Lagrue, "In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation," *Brain Research*, vol. 900, no. 1, pp. 72–79, 2001.
- [47] S. Das, N. Gautam, S. K. Dey, T. Maiti, and S. Roy, "Oxidative stress in the brain of nicotine-induced toxicity: protective role of *Andrographis paniculata* Nees and vitamin E," *Applied Physiology, Nutrition, and Metabolism*, vol. 34, no. 2, pp. 124–135, 2009.
- [48] W. Lei, C. Lerner, I. K. Sundar, and I. Rahman, "Myofibroblast differentiation and its functional properties are inhibited by nicotine and e-cigarette via mitochondrial OXPHOS complex III," *Scientific Reports*, vol. 7, no. 1, article 43213, 2017.
- [49] A. P. Raval, K. R. Dave, I. Saul, G. J. Gonzalez, and F. Diaz, "Synergistic inhibitory effect of nicotine plus oral contraceptive on mitochondrial complex-IV is mediated by estrogen receptor- $\beta$  in female rats," *Journal of Neurochemistry*, vol. 121, no. 1, pp. 157–167, 2012.
- [50] I. K. Sundar, K. P. Maremanda, and I. Rahman, "Mitochondrial dysfunction is associated with Miro1 reduction in lung

- epithelial cells by cigarette smoke," *Toxicology Letters*, vol. 317, pp. 92–101, 2019.
- [51] G. Gobe and D. Crane, "Mitochondria, reactive oxygen species and cadmium toxicity in the kidney," *Toxicology Letters*, vol. 198, no. 1, pp. 49–55, 2010.
- [52] E. A. Belyaeva, V. V. Glazunov, and S. M. Korotkov, "Cd2+-promoted mitochondrial permeability transition: a comparison with other heavy metals," *Acta Biochimica Polonica*, vol. 51, no. 2, pp. 545–551, 2019.
- [53] J. Ciapaite, Z. Nauciene, R. Baniene, M. J. Wagner, K. Krab, and V. Mildaziene, "Modular kinetic analysis reveals differences in Cd2+ and Cu2+ ion-induced impairment of oxidative phosphorylation in liver," *The FEBS Journal*, vol. 276, no. 13, pp. 3656–3668, 2009.
- [54] I. E. Scheffl, "Structure and morphology. Integration into the cell," in *Mitochondria*, 2nd ed, I. E. Scheffl, Ed., pp. 15–47, John Wiley & Sons, New York, 2007.
- [55] A. Tzagoloff, "Mitochondrial Structure and Compartmentalization," in *Mitochondria*, Springer, Boston, 1982.
- [56] D. C. Chan, "Mitochondria: dynamic organelles in disease, aging, and development," *Cell*, vol. 125, no. 7, pp. 1241–1252, 2006.
- [57] L. C. Gomes, G. Di Benedetto, and L. Scorrano, "During autophagy mitochondria elongate, are spared from degradation and sustain cell viability," *Nature Cell Biology*, vol. 13, no. 5, pp. 589–598, 2011.
- [58] Y. S. Yoon, D. S. Yoon, I. K. Lim et al., "Formation of elongated giant mitochondria in DFO-induced cellular senescence: involvement of enhanced fusion process through modulation of Fis1," *Journal of Cellular Physiology*, vol. 209, no. 2, pp. 468–480, 2006.
- [59] B. Aravamudan, A. Kiel, M. Freeman et al., "Cigarette smoke-induced mitochondrial fragmentation and dysfunction in human airway smooth muscle," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 306, no. 9, pp. L840–L854, 2014.
- [60] T. Ahmad, I. K. Sundar, C. A. Lerner et al., "Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: implications for chronic obstructive pulmonary disease," *The FASEB Journal*, vol. 29, no. 7, pp. 2912–2929, 2015.
- [61] K. Ballweg, K. Mutze, M. Konigshoff, O. Eickelberg, and S. Meiners, "Cigarette smoke extract affects mitochondrial function in alveolar epithelial cells," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 307, no. 11, pp. L895–L907, 2014.
- [62] S. Ito, J. Araya, Y. Kurita et al., "PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD pathogenesis," *Autophagy*, vol. 11, no. 3, pp. 547–559, 2015.
- [63] G. Ashrafi and T. L. Schwarz, "The pathways of mitophagy for quality control and clearance of mitochondria," *Cell Death and Differentiation*, vol. 20, no. 1, pp. 31–42, 2013.
- [64] B. Bingol, J. S. Tea, L. Phu et al., "The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy," *Nature*, vol. 510, no. 7505, pp. 370–375, 2014.
- [65] R. J. Youle and D. P. Narendra, "Mechanisms of mitophagy," *Nature Reviews. Molecular Cell Biology*, vol. 12, no. 1, pp. 9–14, 2011.
- [66] S. P. Elmore, T. Qian, S. F. Grissom, and J. J. Lemasters, "The mitochondrial permeability transition initiates autophagy in rat hepatocytes," *The FASEB Journal*, vol. 15, no. 12, pp. 2286–2287, 2001.
- [67] M. Priault, B. Salin, J. Schaeffer, F. M. Vallette, J. P. di Rago, and J. C. Martinou, "Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast," *Cell Death and Differentiation*, vol. 12, no. 12, pp. 1613–1621, 2005.
- [68] G. Twig, A. Elorza, A. J. Molina et al., "Fission and selective fusion govern mitochondrial segregation and elimination by autophagy," *The EMBO Journal*, vol. 27, no. 2, pp. 433–446, 2008.
- [69] D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, "Parkin is recruited selectively to impaired mitochondria and promotes their autophagy," *The Journal of Cell Biology*, vol. 183, no. 5, pp. 795–803, 2008.
- [70] D. P. Narendra, S. M. Jin, A. Tanaka et al., "PINK1 is selectively stabilized on impaired mitochondria to activate Parkin," *PLoS Biology*, vol. 8, no. 1, article e1000298, 2010.
- [71] Y. Chen and G. W. Dorn 2nd, "PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria," *Science*, vol. 340, no. 6131, pp. 471–475, 2013.
- [72] E. S. Vincow, G. Merrihew, R. E. Thomas et al., "The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 16, pp. 6400–6405, 2013.
- [73] J. Araya, K. Tsubouchi, N. Sato et al., "PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis," *Autophagy*, vol. 15, no. 3, pp. 510–526, 2019.
- [74] Y. Konokhova, S. Spendiff, R. T. Jagoe et al., "Failed upregulation of TFAM protein and mitochondrial DNA in oxidatively deficient fibers of chronic obstructive pulmonary disease locomotor muscle," *Skeletal Muscle*, vol. 6, no. 1, p. 10, 2016.
- [75] I. Rahman, S. K. Biswas, L. A. Jimenez, M. Torres, and H. J. Forman, "Glutathione, stress responses, and redox signaling in lung inflammation," *Antioxidants & Redox Signaling*, vol. 7, no. 1–2, pp. 42–59, 2005.
- [76] M. M. Shi, T. Iwamoto, and H. J. Forman, "Gamma-glutamylcysteine synthetase and GSH increase in quinone-induced oxidative stress in BPAEC," *The American Journal of Physiology*, vol. 267, pp. L414–L421, 1994.
- [77] T. Harju, R. Kaarteenaho-Wiik, Y. Soini, R. Sormunen, and V. L. Kinnula, "Diminished immunoreactivity of gamma-glutamylcysteine synthetase in the airways of smokers' lung," *American Journal of Respiratory and Critical Care Medicine*, vol. 166, no. 5, pp. 754–759, 2002.
- [78] M. Tomaki, H. Sugiura, A. Koarai et al., "Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung," *Pulmonary Pharmacology & Therapeutics*, vol. 20, no. 5, pp. 596–605, 2007.
- [79] A. H. Agler, T. Kurth, J. M. Gaziano, J. E. Buring, and P. A. Cassano, "Randomised vitamin E supplementation and risk of chronic lung disease in the Women's Health Study," *Thorax*, vol. 66, no. 4, pp. 320–325, 2011.
- [80] J. de Batlle, E. Barreiro, I. Romieu et al., "Dietary modulation of oxidative stress in chronic obstructive pulmonary disease patients," *Free Radical Research*, vol. 44, no. 11, pp. 1296–1303, 2010.
- [81] C. Michaeloudes, M. B. Sukkar, N. M. Khorasani, P. K. Bhavsar, and K. F. Chung, "TGF- $\beta$  regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 300, no. 2, pp. L295–L304, 2011.

- [82] J. W. Hwang, S. Rajendrasozhan, H. Yao et al., "FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease," *Journal of Immunology*, vol. 187, no. 2, pp. 987–998, 2011.
- [83] Y. Aydemir, O. Aydemir, A. Şengül et al., "Comparison of oxidant/antioxidant balance in COPD and non-COPD smokers," *Heart & Lung*, vol. 48, no. 6, pp. 566–569, 2019.
- [84] A. ben Anes, H. Fetoui, S. Bchir et al., "Increased oxidative stress and altered levels of nitric oxide and peroxynitrite in Tunisian patients with chronic obstructive pulmonary disease: correlation with disease severity and airflow obstruction," *Biological Trace Element Research*, vol. 161, no. 1, pp. 20–31, 2014.
- [85] I. Rahman, E. Swarska, M. Henry, J. Stolk, and W. MacNee, "Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?," *Thorax*, vol. 55, no. 3, pp. 189–193, 2000.
- [86] H. Tavilani, E. Nadi, J. Karimi, and M. T. Goodarzi, "Oxidative stress in COPD patients, smokers, and non-smokers," *Respiratory Care*, vol. 57, no. 12, pp. 2090–2094, 2012.